Перспективы применения внутривенного иммуноглобулина при аутоиммунных ревматических заболеваниях
https://doi.org/10.14412/1996-7012-2014-1-45-52
Аннотация
Проанализированы данные литературы об эффективности внутривенного иммуноглобулина (ВВИГ) при аутоиммунных ревматических заболеваниях (РЗ). ВВИГ является препаратом выбора при болезни Кавасаки, идиопатической тромбоцитопенической пурпуре, дерматомиозите и др. Применение ВВИГ у больных с РЗ целесообразно при иммунодефиците, инфекционных осложнениях, неэффективности глюкокортикоидов и цитостатиков в случае развития аутоиммунной цитопении, поражении ЦНС и васкулите. При антифосфолипидном синдроме ВВИГ может быть эффективным при угрозе потери плода и отсутствии эффекта антикоагулянтов.
Об авторах
Елена Александровна Асеева
ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва, Россия; 115522, Москва, Каширское ш., 34А
Россия
Россия
S K Solov’ev
ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва, Россия; 115522, Москва, Каширское ш., 34А
Россия
Россия
Литература
1. <div><p>Кондратенко ИВ, Заплатников АЛ, Бологов АА. Внутривенные иммуноглобулины: что и когда? (Лекция). Детская больница. 2010;4:56–60. [Kondratenko IV, Zaplatnikov AL, Bologov AA. Intravenous immunoglobulins: the what and when? (Lectur). Detskaya bol'nitsa. 2010;4:56–60.]</p><p>Schultze HE, Schwick G. On new possibilities of intravenous gamma globulin administration. Dtsch Med Wochenschr. 1962 Aug;24(87):1643–4. DOI: http://dx.doi.org/10.1055/s-0028-1113997.</p><p>Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human gamma-globulin. Vox Sang. 1962;7:157–74. DOI: http://dx.doi.org/10.1111/j.1423-0410.1962.tb03240.x.</p><p>Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001 Sep 6;345(10):747–55. DOI: http://dx.doi.org/10.1056/NEJMra993360.</p><p>Аверченков ВМ, Палагин ИС. Внутривенные иммуноглобулины: механизмы действия и возможности клинического применения. Клиническая микробиологическая и антимикробная химиотерапия. 2004:6(3):273–81. [Averchenkov VM, Palagin IS. Vnutrivennye immunoglobuliny: mekhanizmy deistviya i vozmozhnosti klinicheskogo primeneniya. Klinicheskaya mikrobiologicheskaya i antimikrobnaya khimioterapiya. 2004:6(3):273–81.]</p><p>Imbach P. Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. Swiss Med Wkly. 2012;142:w13593. DOI: 10.4414/smw.2012.13593.</p><p>Cоловьев СК. Внутривенный иммуноглобулин в ревматологической практике. Специальный выпуск. Доктор.Ру. 2012;20–25. Доступ по ссылке: http://www.pharmapf.ru/downloads/Doctor_ru_chel_i_lek_2012.pdf. [Colov'ev SK. Vnutrivennyi immunoglobulin v revmatologicheskoi praktike. Spetsial'nyi vypusk. Doktor.Ru. 2012;20–25. Available from: http://www.pharmapf.ru/downloads/Doctor_ru_chel_i_lek_2012.pdf.]</p><p>Fridmann W. Regulation of B-cell activation and antigen presentation by Fc receptors. Curr Opin Immunol. 1993;53(5):355–60. DOI: http://dx.doi.org/10.1016/0952-7915(93)90053-U.</p><p>Yu Z, Lennon V. Mechanism of intravenous immune globulin therapy in antibodymediated autoimmune diseases. N Engl J Med. 1999;340(3):227–8. DOI: http://dx.doi.org/10.1056/NEJM199901213400311.</p><p>Bleeker W, Teeling J, Hack C. Accelerated autoantibody clearance by intravenous immunoglobulin therapy experimental models to determine the magnitude and time course of the effect. Blood. 2001;98(10):3136–42. DOI: http://dx.doi.org/10.1182/blood.V98.10.3136.</p><p>Mollnes T, Hogasen K, Hoass B, et al. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependet on the ig isitype and its C1 binding properties. Scand J Immunol. 1995;41(5):449–56. DOI: http://dx.doi.org/10.1111/j.1365-3083.1995.tb03591.x.</p><p>Imbach P, Barandun S, d'Apuzzo V, et al. High dose intravenous gammaglobulins for idiopatic thrombocytopenic purpura in child-hood. Lancet. 1981;1(8232):1228–30. DOI: http://dx.doi.org/10.1016/S0140-6736(81)92400-4.</p><p>Aschermann S, Lux A, Baerenwaldt A, et al. The other side of mmunoglobulin G: suppressor of inflammation. Clin Exp Immunol. 2010 May;160(2):161–7. DOI: http://dx.doi.org/10.1111/j.1365-2249.2009.04081.x.</p><p>Wenderfer SE, Thacker T. Intravenous Immunoglobulin in the Management of Lupus Nephritis. Autoimmune Dis. 2012;2012:589359. DOI: 10.1155/2012/589359. Epub 2012 Sep 27.</p><p>Popescu A, Kao AH. Neuropsychiatric systemic lupus erythematosus. Curr Neuropharmacol. 2011 Sep;9(3):449–57. DOI: http://dx.doi.org/10.2174/157015911796557984.</p><p>Paschal RD, Neff AT. Resolution of Hypoprothrombinemia-Lupus Anticoagulant Syndrome (HLAS) after multidrug therapy with rituximab: a case report and review of the literature. Haemophilia. 2013 Mar;19(2):e62–5. DOI: 10.1111/hae.12027. Epub 2012 Sep 19</p><p>Ballow M, Parke A. The uses of intravenous immune globulin in collagen vascular disorders. J Allergy Clin Immunol. 1989;84(4 Pt 2):608–12. DOI: http://dx.doi.org/10.1016/0091-6749(89)90198-X.</p><p>Maier WP, Gordon DS, Howard RF, et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus associated thrombocytopenia. Arthritis Rheum. 1990;33(8):1233–9. DOI: http://dx.doi.org/10.1002/art.1780330825.</p><p>Kuwana M, Kaburaki J, Okazaki Y, et al. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2006;45(7):851–4. DOI: http://dx.doi.org/10.1093/rheumatology/kel010. Epub 2006 Jan 17.</p><p>Levy Y, Sherer Y, George J, et al. Intravenous immunoglobulin treatment in lupus nephritis. Semin Arthritis Rheum. 2000;29(5):321–7. DOI: http://dx.doi.org/10.1016/S0049-0172(00)80018-9.</p><p>Francioni C, Galeazzi M, Fioravanti A, et al. Long term IVIG treatment in systemic lupus erythematosus. Clin Exp Rheumatol. 1994;12(2):163–8.</p><p>Schroeder JO, Zeuner RA, Euler HH, Löffler H. High dose intravenous gammaglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol. 1996;23(1):71–5.</p><p>Lin C, Hsu HC, Chiang H. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high dose intravenous gamma globulin. Nephron. 1989;53(4):303–10. DOI: http://dx.doi.org/10.1159/000185772.</p><p>Levy Y, Sherer Y, George J, et al. Intravenous immunoglobulin treatment in lupus nephritis. Semin Arthritis Rheum. 2000;29(5):321–7. DOI: http://dx.doi.org/10.1016/S0049-0172(00)80018-9.</p><p>Bolitis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet. 1999;354(9178):569–70. DOI: http://dx.doi.org/10.1016/S0140-6736(99)01575-5.</p><p>Sherer Y, Kuechler S, Jose Scali J, et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J. 2008 Jan;10(1):55–7.</p><p>Kim J-M, Kwok SK, Ju JH, et al. Reactive hemophagocytic syndrome in adult Korean patients with systemic lupus erythematosus: a case-control study and literature review. J Rheumatol. 2012 Jan;39(1):86–93. DOI: 10.3899/jrheum.110639. Epub 2011 Dec 15</p><p>Kessel A, Ammuri H, Peri R, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol. 2007;179(8):5571–5.</p><p>Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011 Feb;127(2):303–12. DOI: 10.1016/j.jaci.2010.12.1087.</p><p>Gobert D, Bussel JB, Cunningham-Rundles C, et al. Efficacy and safety of rituximab in common variable immunodeficiencyassociated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol. 2011;155(4):498–508. DOI: 10.1111/j.1365-2141.2011.08880.x. Epub 2011 Oct 8.</p><p>Muscat С., Bertotto A, Ercolani R, et al. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins:effects on disease activity and serum cytokines. Ann Rheumatic Dis. 1995;54(5):382–5. DOI: http://dx.doi.org/10.1136/ard.54.5.382.</p><p>Lehmann HW, Plentz A, Von Landenberg, et al. Intravenous immunoglobulin treatment of four patients withuvenile polyarticular arthritis associated with persistent parvovirus B19 infection and antiphospholipid antibodies. Arthritis Res Ther. 2004;6(1):R1–R6. DOI: http://dx.doi.org/10.1186/ar1011. Epub 2003 Oct 10.</p><p>Newburger JW. The treatment of Kawasaki disease with intravenous immunoglobulin. N Engl J Med. 1986;315:341–7. DOI: http://dx.doi.org/10.1056/NEJM198608073150601.</p><p>Boman S, Ballen JL, Seggev JS. Dramatic responses to intravenous immunoglobulin in vasculitis. J Intern Med. 1995;238(4):375–7. DOI: http://dx.doi.org/10.1111/j.1365-2796.1995.tb01213.x.</p><p>Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole for systemic vasculitis. Br J Rheumatol. 1996;35(11):1150–3. DOI: http://dx.doi.org/10.1093/rheumatology/35.11.1150.</p><p>Jayne DR, Davies MJ, Fox CJ, et al. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991;331(8750):1137–9. DOI: http://dx.doi.org/10.1016/0140-6736(91)92797-6.</p><p>Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistant disease activity. QJM. 2000;93(7):433–9. DOI: http://dx.doi.org/10.1093/qjmed/93.7.433.</p><p>Levy Y, Sherer Y, George J, et al. Serological and clinical response to treatment systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol. 1999;119(3):231–8. DOI: http://dx.doi.org/10.1159/000024199.</p><p>Lang BA, Laxer RM, Murphy G, et al. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med. 1991 Aug;91(2):169–72. DOI: http://dx.doi.org/10.1016/0002-9343(91)90010-U.</p><p>Collet E, Dalac S, Maerens B et al. Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol. 1994 Feb;130(2):231–4. DOI: http://dx.doi.org/10.1111/j.1365-2133.1994.tb02906.x.</p><p>Barron KS, Sher MR, Silverman ED, et al. Intravenous immunoglobulin therapy: magic or black magic. J Rheumatol Suppl. 1992 Apr;33:94–7.</p><p>Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis–four year review of nine cases. Arch Dis Child. 1995 Jan;72(1):25–8. DOI: http://dx.doi.org/10.1136/adc.72.1.25.</p><p>Marie I, Menard JF, Hatron PY, et al. Intravenous immunoglobulins for steroidrefractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken). 2010 Dec;62(12):1748–55. DOI: 10.1002/acr.20325.</p><p>Cherin P. Current therapy for polymyositis and dermatomyositis. Rev Med Interne. 2008 Jun; 29 Spec No 2:9–14.</p><p>Cherin P. Treatment by IgIV of polymyositis and dermatomyositis: literature review. Rev Med Interne. 2004 Dec;25 Spec No 3:6–9.</p><p>Cherin P, Grivel T. Immunoglobulins: multiple potential therapeutic proteins for use in autoimmune disorders. Rev Med Interne. 2010 Dec;31(9 Suppl):H12–6. DOI: http://dx.doi.org/10.1016/S0248-8663(10)70008-4.</p><p>Dalakas MC. Inflammatory myopathies: management of steroid resistance. Curr Opin Neurol. 2011 Oct;24(5):457–62. DOI: http://dx.doi.org/10.1097/WCO.0b013e32834a9589.</p><p>Carreras LO, Perez GN, Vega HR, Casavilla F. Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet. 1988 Aug 13;2(8607):393–4. DOI: http://dx.doi.org/10.1016/S0140-6736(88)92859-0.</p><p>Barbui T, Finazzi G, Falanga A, Cortelazzo S. Intravenous gammaglobulin, antiphospholipid antibodies, and thrombocytopenia. Lancet. 1988 Oct 22;2(8617):969. DOI: http://dx.doi.org/10.1016/S0140-6736(88)92642-6.</p><p>Sun XG, Liu XY, Zhu R, et al. Effectiveness of intravenous immunoglobulin therapy in treating unexplained recurrent spontaneous abortion and its effect on the level of serum soluble human leucocyte antigen G. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2010 Oct;32(5):483–7. DOI: 10.3881/j.issn.1000-503X.2010.05.002.</p><p>Baleva M, Nikolov K. The role of intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis. Int J Rheumatol. 2011;2011:829751. DOI: 10.1155/2011/829751.</p><p>Bennet P, Peterson P, Sangle S, et al. Adult Still disease and collapsing glomerulopathy: successful treatment with intravenous immunoglobulin and mycophenolate mofetil. Rheumatology (Oxford). 2004;43(6):795–9. DOI: http://dx.doi.org/10.1093/rheumatology/keh172. Epub 2004 Mar 23.</p><p>Kizawa M, Mori K, Iijima M, et al. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry. 2006;77(8):967–9. DOI: http://dx.doi.org/10.1136/jnnp.2005.084533.</p></div><br />
Рецензия
Для цитирования:
Асеева Е.А., Solov’ev S.K. Перспективы применения внутривенного иммуноглобулина при аутоиммунных ревматических заболеваниях. Современная ревматология. 2014;8(1):45-52. https://doi.org/10.14412/1996-7012-2014-1-45-52
For citation:
Aseeva E.A., Solov’ev S.K. Intravenous immunoglobulin: prospects in patients with autoimmune rheumatic diseases. Modern Rheumatology Journal. 2014;8(1):45-52. (In Russ.) https://doi.org/10.14412/1996-7012-2014-1-45-52
Просмотров: 1274
Послать статью по эл. почте 